This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Metabolic disease				
Dyslipidemia	Farnesoid X receptor (FXR; NR1H4)	<p>Studies in rodents and in nonhuman primates identified a tetrahydroazepinoindole-based FXR agonist that could help treat dyslipidemia. In a mouse model of dyslipidemia, the FXR agonist decreased serum low-density lipoprotein cholesterol (LDL cholesterol) levels compared with vehicle control ($p < 0.01$). In female rhesus monkeys, the agonist significantly reduced serum triglycerides, very low-density lipoprotein cholesterol (VLDL cholesterol) and LDL cholesterol compared with vehicle ($p < 0.05$ for all). Next steps could include evaluating the FXR agonist in additional animal models of dyslipidemia.</p> <p>SciBX 3(7); doi:10.1038/scibx.2010.217 Published online Feb. 18, 2010</p>	Patent and licensing status unavailable	<p>Lunquist, J.T. <i>et al. J. Med. Chem.</i>; published online Jan. 22, 2010; doi:10.1021/jm901650u</p> <p>Contact: Douglas C. Harnish, Wyeth Research, Collegeville, Pa. e-mail: harnisd@wyeth.com</p> <p>Contact: Joseph T. Lundquist IV, same affiliation as above e-mail: lundquj@wyeth.com</p>